OBI Pharma Long Term Debt

OBI Pharma (4174.TWO) currently reports a long-term debt of $260M as of June 2026. That compares with $410M in the prior-year period — down 35.4% year over year. Use the charts on this page to explore OBI Pharma's long-term debt history and peer comparisons.

OBI Pharma's long-term debt decreased from $410M to $260M — a 35.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

OBI Pharma reported $260M in long-term debt as of June 2026. That compares with $410M in the prior-year period — down 35.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $260M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for OBI Pharma, and consider following 4174.TWO for alerts when major investors trade the stock.

OBI Pharma is classified in the Healthcare sector. On long-term debt, it currently shows $260M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4174.TWO with unrelated industries.